The Subject Expert Committee (SEC) of India’s Central Drugs Standard Control Organization (CDSCO) has given its recommendation to Novo Nordisk’s trial of the anti-diabetic drug semaglutide in India. Semaglutide,  a glucagon-like peptide 1 (GLP 1) analog used to manage type 2 diabetes along with lifestyle changes such as dietary management and optimum physical activity, was approved by the FDA for subcutaneous injection as early as 2017. The Danish insulin maker justified that the international clinical trials have determined the drug’s efficacy in reducing glycosylated hemoglobin (HbA1c) levels and body weight, and the SEC’s recommendation is based on this submission.